#SOHO2024: Aggressive B-cell non-Hodgkin lymphoma

To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up on our live social media coverage relating to aggressive B-cell non-Hodgkin lymphoma below.

CONGRESS | #SOHO2024 | POSTER@DrRaulCordoba @Hospital_FJD presents long-term data from the phase I/II EPCORE NHL-2 trial of epcoritamab + GemOx in a larger cohort of pts with transplant-ineligible R/R #DLBCL, with a focus on complete responders and 2L patients. N=103, ORR were… pic.twitter.com/wb475oUBDC

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Frederick Locke, @MoffittNews, talks about CAR T-cell therapy after CAR T-cell therapy for DLBCL. He discusses factors affecting its effectiveness such as immune status within the tumor cells, tumor IFN signaling, suppressive features, target, and the CAR… pic.twitter.com/z57tzjPTIR

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Christopher Yasenchak, Willamette Valley Cancer Institute, shares results from the phase III ECHELON-3 study of brentuximab vedotin in combination with len and rituximab for R/R DLBCL.
Median PFS 4.2 mo, OS 13.8 mo, ORR 64%, CR 40%, AEs were managed with dose… pic.twitter.com/vQ6hK7km2A

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024
Jason Westin @Lymphoma_Doc @MDAndersonNews shares data from the phase Ib trial of GOLCA+R-CHOP as 1L therapy in aggressive B-cell #lymphoma. ORR 0.2mg 82% and 0.4mg 88%, uMRD 0.2mg 73% and 0.4mg 90%, median DoR NR in either group, 12-mo PFS 0.4mg 85%, 120-mo… pic.twitter.com/uPhpTo9lZX

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024@AstridPavlovsky, Fundaleu, Buenos Aires, discusses accessing novel therapies for aggressive lymphoma; concluding that while there are significant advances in the management of lymphomas, there remains discrepancies in access to novel therapies and clinical… pic.twitter.com/DDEJpuA4il

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | #SOHO2024@gilles_salles @MSKCancerCenter discusses how to sequence therapies in R/R DLBCL, with the aim to optimize the chance of cure; concluding with a look to the future landscape and the possibility of achieving a cure amongst a substantial fraction of patients.… pic.twitter.com/wqZN2SS7sd

— Lymphoma Hub (@lymphomahub) September 6, 2024

CONGRESS | POSTER | #SOHO2024 |
Ning Dong @NingDong9 presents single center experience of SoC epcoritamab for R/R #LBCL (N=26). In this heavily pretreated population, the CR rate was 18.9% at median follow-up of 4 months, with PR in 31.8%. #lymphoma #lymsm #MedicalCongress pic.twitter.com/bPZ8sIw2zt

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Yasmin Karimi @Yhkarimi presents extended follow-up data beyond 2.5 years from the pivotal expansion cohort of the phase II EPCORE NHL-1 study of epcoritamab monotherapy in R/R #DLBCL (N=157). Of pts with a CR (n=65) 54% remained in CR at 30… pic.twitter.com/mkTvkPIput

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Martin Hutchings @DocHutchings presents extended follow-up from a pivotal phase II study of glofitamab monotherapy in pts with R/R #DLBCL (N=155) and subgroup analysis in pts with prior CAR-T cell therapy (N=52). Overall ORR was 52% with overall CR… pic.twitter.com/m5DMB3SQwN

— Lymphoma Hub (@lymphomahub) September 4, 2024

CONGRESS | POSTER | #SOHO2024 | Daniel Kerr presents first results from the phase Ib/II EPCORE NHL-5 study investigating subcutaneous epcoritamab + pola-R-CHP as 1L treatment for #DLBCL (N=37). The ORR was 100% with CR 89%, demonstrating that epcoritamab can be combined with 1L… pic.twitter.com/9hGxqQxpNt

— Lymphoma Hub (@lymphomahub) September 4, 2024